EUVIMEDEUVIMED entdecken
Open Access

MSC-encapsulated porous microparticle eye drops for autoimmune dry eye disease treatment in NOD mice

Taige Chen iD, Rui Liu iD, Qin Chen iD, Xuebing Feng iD, Bin Kong iD, Yuanjin Zhao iD

Science Advances · 2025

DOI: 10.1126/sciadv.adu9772 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Taige Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Ch…. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Mesenchymal Stem Cells, Ophthalmic Solutions, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dry eye disease (DED) is characterized by chronic inflammation and an unstable tear film. Stem cells have shown potential for DED treatment, but the main challenge lies in improving cell delivery effectiveness. Here, we developed eye drops for autoimmune DED treatment using porous arginine–glycine–aspartic acid (RGD)–modified alginate microcarriers with mesenchymal stem/stromal cells (MSCs) (RGD-Alg@MSCs). These microcarriers provided a favorable microenvironment for large-scale cell expansion while maintaining stemness with ideal mechanical properties for ocular application. In vitro, RGD-Alg@MSCs demonstrated significantly enhanced therapeutic effects compared to conventional MSCs, including improved cell viability, reduced apoptosis and reactive oxygen species, and enhanced release of immunomodulatory factors. Transcriptomic analysis revealed distinct molecular mechanisms underlying these enhanced therapeutic effects. In the mouse model, RGD-Alg@MSCs exhibited prolonged ocular retention and enhanced tear production, promoted corneal healing, and suppressed inflammation by inhibiting dendritic cell activation and T H 17 differentiation. Our microcarrier system substantially improves stem cell delivery efficiency for treating autoimmune DED.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dry Eye SyndromesMesenchymal Stem CellsOphthalmic SolutionsMesenchymal Stem Cell TransplantationAutoimmune DiseasesAnimalsMiceDisease Models, AnimalPorosityMice, Inbred NODAlginatesHumansOligopeptidesTh17 CellsCell Survival

Substanzen

Ophthalmic SolutionsAlginatesarginyl-glycyl-aspartic acidOligopeptides

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
  • Department of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen, Guangdong 518000, China.

ORCID-Profile: Taige Chen, Rui Liu, Qin Chen, Xuebing Feng, Bin Kong, Yuanjin Zhao

Zitieren

APA

Chen, T., Liu, R., Chen, Q., Feng, X., Kong, B., & Zhao, Y. (2025). MSC-encapsulated porous microparticle eye drops for autoimmune dry eye disease treatment in NOD mice. Science Advances. https://doi.org/10.1126/sciadv.adu9772

Vancouver

Chen T, Liu R, Chen Q, Feng X, Kong B, Zhao Y. MSC-encapsulated porous microparticle eye drops for autoimmune dry eye disease treatment in NOD mice. Science Advances. 2025. doi:10.1126/sciadv.adu9772

BibTeX
@article{Chen2025,
  author = {Chen, Taige and Liu, Rui and Chen, Qin and Feng, Xuebing and Kong, Bin and Zhao, Yuanjin},
  title = {MSC-encapsulated porous microparticle eye drops for autoimmune dry eye disease treatment in NOD mice},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adu9772}
}
Kostenlos starten →